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LETTERS TO THE EDITOR
Anabolic Steroid-Induced Echocardiographic
Characteristics of Professional Football Players?
We read with great interest the study by Abernethy et al. entitled
“Echocardiographic Characteristics of Professional Football Play-
ers” (1). The investigators report on a high relative wall thickness
of 0.424, reflecting an emphasis on strength training.
Although the investigators state that “steroid use among the
participants was not known,” no data are presented to underline
this important statement, nor is the possibility of an anabolic
steroid-induced hypertrophy discussed. It is well known that
anabolic steroid use is not uncommon among professional football
players as the National Football League does not perform doping
tests as required by the World Anti-Doping Agency (WADA)
among professional athletes of most other sports. To prove the
investigators’ statement of having examined steroid-free football
players, a screening test for doping substances could have been
performed, or at the least parameters of clinical chemistry which
are altered by the use of anabolic steroids (e.g., follicle-stimulating
hormone, luteinizing hormone, sex-hormone binding globulin,
cholesterol, low-density lipoprotein, high-density lipoprotein, ala-
nine aminotransferase) should have been given in the paper. The
researchers also do not present data on diastolic function, which
may be restricted in anabolic steroid users and thereby contribute
to a differentiation between a physiological and pathological
myocardial hypertrophy (2–5). Furthermore, a description of the
athletes’ training history (years of training, hours per week spent
for strength training) would have been helpful.
As reported previously, the relative wall ratio in anabolic-free
soccer players, rowers, weightlifters, and bodybuilders usually is
about 0.40 and differs significantly from higher values in anabolic
steroid-using bodybuilders (5). This influence of anabolic steroids
on the left ventricular wall has also been demonstrated by others
(2–4,6). Additionally, the cited study of Pelliccia et al. (7) found a
left ventricular wall thickness of 13 mm in only 1.7% (15 rowers
or canoists and 1 cyclist—each of them having a left ventricular
end-diastolic diameter 54 mm) in 947 athletes, whereas Aber-
nethy et al. (1) present about 28% of the football players having a
left ventricular wall thickness of 13 mm in their Figure 2, but
they only mention 11% (17 of 156) with more than 13 mm in the
Results section, which are cited as 6% in the Discussion section of
their study (1).
Furthermore, Abernethy et al. (1) do not cite their used
echocardiographic convention and probably determined myocar-
dial wall thickness by the Penn-Convention (8) (otherwise the use
of the Penn-Cube formula [8] for left ventricular mass determi-
nation is not admissible). Because the Penn-Convention (8)
excludes the epi- and endocard from septal and posterior myocar-
dial wall thickness, an underestimation compared to the data of
Pelliccia et al. (7), who determined the myocardial wall thickness
by use of the convention of the American Society of Echocardi-
ography (9), has to be presumed.
Therefore, we do not share the opinion that the data presented
allow for the conclusion that a strength-training-induced high
relative wall thickness in professional football players reflects a
physiologically induced (concentric) hypertophy.
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REPLY
Dr. Scharhag and colleagues raise the important point that steroid
use among the athletes may have affected echocardiographic
features of presumably healthy elite football players. Anabolic
steroids are commonly used to enhance athletic performance and
muscle development and may have deleterious effects. Hyperten-
sion, ventricular remodeling, myocardial ischemia, and sudden
cardiac death have each been temporally and causally associated
with anabolic steroid use in humans (1). However, studies exam-
ining the effects of anabolic steroids on myocardial structures have
not been consistent, and the topic remains controversial (2,3).
Surveys of U.S. football players at the high school level suggest that
more than 6% had used anabolic steroids (4). However, even
though we were unable either to question the participants or to
perform blood tests for steroid use as part of our study, National
Football League (NFL) players are subject to year-round testing.
Therefore, it would be very difficult for them to use these
substances.
The number of subjects with thickened ventricular walls is
correctly shown in the histogram of Figure 2 of our report.
Actually, 30% (47 of 156 subjects) had a wall thickness 13 mm.
The statement in the Discussion section of our report that “six
percent of the football players in our series had a wall thickness in
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the borderline range of 13 mm” was in error. Six percent had a
wall thickness of14 mm as stated in the caption of Figure 2. The
incidence of intraventicular septal thickness of more than 13 mm
(14 to 16 mm) was 11% (17 of 156 subjects) as stated in the Results
section. The incidence of either the intraventricular septal wall or
left ventricular free wall being more than 13 mm was actually
higher (13%; 20 of 156 subjects).
The findings presented in our study demonstrate the chamber
size, wall thickness, and ejection fraction of elite professional
American football players in the NFL. Because both the size and
the types of physical effort of these players are different from those
of bodybuilders, rowers, canoists, or cyclists, we believe these
observations will be useful in separating physiologic adaptations
from pathologic findings when evaluating such players.
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Cellular Myocardial
Reconstruction Using Human Myoblasts
The Expedited Review from Pagani et al. (1) and the Research
Letter from Hagege et al. in The Lancet (2) are the first reports that
provide evidence about the fate of human myoblasts posttransplan-
tation. Before these reports appeared there was no histological
evidence on the viability and in vivo behavior of the human
myoblasts after engraftment into the myocardium. These are
significant findings and may provide clues to the unanswered
questions impeding the progress in heart cell therapy using
myoblasts. Moreover, these reports will provide impetus to the
efforts in defining the basic mechanism underlying cardiac function
improvement in postmyoblast transplantation.
Pagani et al. (1) showed that transplanted myoblasts developed
into myotubes and expressed human myosin heavy chain (slow
isoform) in the myocardium. The myofibers originating from the
myoblasts aligned in accordance with the heart muscle architec-
ture. These results may resolve the controversy surrounding the
milieu-dependent trans-differentiation of myoblasts into cardio-
myocytes. The absence of connexin-43 expression, however, con-
firms the lack of electrical integration between the skeletal myo-
fibers and the surrounding cardiac tissue. Without such linkage, it
will be difficult for the cell graft to synchronize its contractility with
the myocardium.
Considering the difficulties of using human subjects as a model,
we developed a porcine heart model of myocardial infarction with
immune tolerance in order to study the in vivo behavior of the
human myobalsts and to define the underlying mechanism of
global improvement in the left ventricular pump function. We
observed the persistence of lac-z reporter gene carrying human
myoblasts for up to seven months in the porcine heart (3). The
xenografted myoblasts expressed human skeletal muscle myosin
heavy chain (slow isoform) at the site of transplantation. Similar to
the results obtained by Pagani et al. (1), we observed that the cells
followed the geometric organization of the host tissue. An inter-
esting finding of our study—based on histochemistry and fluores-
cent in situ hybridization analysis using a cocktail of probes specific
for human and porcine chromosomes—is the presence of hetero-
karyons in the host myocardium resulting from the fusion between
the donor myoblasts and the recipient cardiomyocytes. This
hypothesis is substantiated by the long-term survival of the
xenograft even after the discontinuation of immunosuppression
(3). The observation of myofibers expressing both slow and fast
isoforms of myosin by Hagege et al. (2) may be due to spontaneous
fusion between myoblasts and the cardiomyocytes. We believe that
together with other proposed mechanisms, formation of mosaic
muscle fibers is the underlying mechanism in the improvement of
cardiac function.
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